文献速递妇产影像US

妊娠11-13周筛查三体综合征:使用妊娠相关血浆蛋白-A、胎盘生长因子或两者

Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
PubMed 文献 · Ultrasound Obstet Gynecol · 2020-01-01

这项前瞻性筛查研究纳入71266例单胎妊娠,评估在11-13周联合筛查21、18、13三体时用PlGF替代PAPP-A的影响。结果显示PAPP-A是首选的生化标志物,尤其在11周或更早检测时;若用PlGF替代PAPP-A可达相同检出率但假阳性率更高。

要点

  • 11-13周联合筛查三体时,PAPP-A是首选的生化标志物而非PlGF。
  • 11周或更早进行生化检测时筛查性能优于13周。
  • 若用PlGF替代PAPP-A可达相同检出率但假阳性率更高。

核心结论

  • 在早孕期三体筛查中首选的生化标志物是PAPP-A而非PlGF,尤其当生化检测在妊娠11周或更早进行时。
  • 若用PlGF替代PAPP-A可达相同检出率但假阳性率更高,这可能是兼顾三体与子痫前期筛查成本效益的可接受折中。

研究设计与样本

  • 前瞻性筛查研究,纳入71266例单胎妊娠,在11-13周联合母亲年龄、胎儿颈项透明层厚度及血清PAPP-A和游离β-hCG筛查21、18、13三体,并同时测定PlGF。
  • 数据集随机分为大致等量的训练集与测试集,用训练集获得的PlGF参数用于测试集风险计算。
  • 采用标准化检出率计算方法,将生化与NT似然比应用于12至50岁各年龄,并按2018年英格兰和威尔士三体妊娠母亲年龄分布加权。

诊断标准与关键数值

  • 研究人群包含70858例(99.4%)胎儿核型正常或出生表型正常新生儿,263例21三体、109例18三体和36例13三体。
  • 联合试验筛查21三体在5%假阳性率下,11、12、13周检测的检出率分别为94%、90%、84%;用PlGF替代PAPP-A的相应值分别为90%、87%、86%。
  • 在本研究人群平均检测孕周12.7周时,母亲年龄、胎儿NT、血清游离β-hCG和PAPP-A筛查在5%假阳性率下对21、18、13三体的检出率分别为88%、96%、97%;用PlGF替代PAPP-A的相应值分别为85%、96%、96%。
  • 在21三体妊娠中,PAPP-A中位MoM偏离正常随孕周增加而减小,而PlGF的偏离不随孕周变化。
  • 在妊娠11周和12周期间,筛查包含PAPP-A优于包含PlGF;在13周期间,使用PlGF的筛查性能略高于PAPP-A。

临床应用与阅片要点

  • 早孕期三体筛查报告中应优先采用PAPP-A作为生化标志物,尤其在11周或更早检测时。
  • 若因兼顾子痫前期筛查而采用PlGF替代PAPP-A,需注意相同检出率下假阳性率更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Serum pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF) at 11-13 weeks' gestation are reduced in pregnancies with fetal trisomy and in those that subsequently develop pre-eclampsia (PE). In screening for trisomy, the established biochemical marker is PAPP-A, whereas in screening for PE, the preferred marker is PlGF. The objective of this study was to examine the impact of replacing PAPP-A by PlGF in first-trimester screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency thickness (NT) and free β-human chorionic gonadotropin (β-hCG).

METHODS: This was a prospective screening study in singleton pregnancies for trisomies 21, 18 and 13 by a combination of maternal age, fetal NT and serum PAPP-A and free β-hCG at 11-13 weeks' gestation in which we also measured PlGF. Multiples of the median (MoM) values were calculated for PAPP-A, free β-hCG and PlGF. The dataset was split randomly into training and test datasets of roughly equal size, and the parameters for PlGF obtained from the training dataset were used in risk calculation for the test dataset. Standardized detection rates were computed by obtaining the likelihood ratios for biochemistry and fetal NT for trisomy-21, -18 and -13 pregnancies in the sample and then applying these to each year of maternal age from 12 to 50 to estimate the age-specific detection rates. These were then weighted according to the maternal age distributions of trisomy-21, -18 and -13 pregnancies in England and Wales in 2018. Similarly, standardized false-positive rates (FPR) were computed by obtaining the likelihood ratios for biochemistry and NT, as appropriate, in normal pregnancies in the sample and then applying these to each year of maternal age from 12 to 50 to estimate the age-specific FPRs. A modeling approach was used to assess the performance of screening according to gestational age at biochemical testing.

RESULTS: The study population of 71 266 pregnancies included 70 858 (99.4%) with normal fetal karyotype or birth of a phenotypically normal neonate and 263 with trisomy 21, 109 with trisomy 18 and 36 with trisomy 13. There are five main findings of this study. First, the performance of screening for trisomy by the first-trimester combined test or the combined test in which PAPP-A is replaced by PlGF is substantially better at 11 than at 13 weeks' gestation; for example, the detection rates of trisomy 21 by the combined test were 94%, 90% and 84%, at 5% FPR, when testing was carried out at 11, 12 and 13 weeks, respectively, and the corresponding values in screening by a test in which PAPP-A is replaced by PlGF were 90%, 87% and 86%, respectively. Second, in trisomy-21 pregnancies, the deviation of median PAPP-A MoM from normal decreases with increasing gestational age, whereas the deviation in PlGF does not change with gestational age. Third, the performance of screening for trisomy 21 during the 11th and 12th gestational weeks is superior if screening includes PAPP-A rather than PlGF, whereas during the 13th week the performance is slightly higher with the use of PlGF rather than PAPP-A. Fourth, in our population with mean gestational age at testing of 12.7 weeks, screening by maternal age, fetal NT, serum free β-hCG and serum PAPP-A predicted 88%, 96% and 97% of cases of fetal trisomies 21, 18 and 13, respectively, at a FPR of 5%; the respective values in screening by a test in which PAPP-A is replaced by PlGF were 85%, 96% and 96%. Fifth, addition of serum PlGF does not improve the prediction of trisomy provided by maternal age, fetal NT and serum free β-hCG and PAPP-A.

CONCLUSION: In first-trimester screening for trisomy, the preferred biochemical marker is PAPP-A rather than PlGF, especially when biochemical testing is carried out during the 11th week of gestation or earlier. However, if PlGF was to be used rather than PAPP-A, the same detection rate can be achieved but at a higher FPR. This may be an acceptable compromise to minimize cost and achieve effective screening for both trisomy and PE. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Mazer Zumaeta A, Wright A, Syngelaki A, et al. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet Gynecol. 2020. PMID: 32621353. doi:10.1002/uog.22140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。